|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.442 EUR | +0.79% |
|
+0.02% | -11.76% |
| 04-15 | European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading | MT |
| 04-14 | European Equities Traded in the US as ADRs Rise in Tuesday Trading | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biopharma | 3.81B | 5.01B | 5.56B | 6.14B | 6.49B | |||||
Total Assets | 9.5B | 13.23B | 13.35B | 14.3B | 13.41B | |||||
CAPEX | -350M | - | - | - | - | |||||
EBITDA | - | - | - | - | 1.75B | |||||
D&A | 228M | 294M | 329M | 328M | 345M | |||||
Operating Income | 659M | 791M | 904M | 1.27B | 1.4B | |||||
Bio Supplies | 226M | 146M | 160M | 216M | 154M | |||||
Total Assets | 101M | 342M | 380M | 349M | 283M | |||||
CAPEX | -13.84M | - | - | - | - | |||||
EBITDA | - | - | - | - | 49M | |||||
D&A | 2.95M | 5.76M | 9.28M | 9.3M | 9M | |||||
Operating Income | 45.99M | 114M | 43.56M | 47.79M | 40M | |||||
Raw Materials and Others | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Medical Testing, Analyzing, and Diagnostic Equipment | ||||||||||
Diagnostic | 779M | 671M | 670M | 645M | 640M | |||||
Total Assets | 3.51B | 3.68B | 3.53B | 3.75B | 3.39B | |||||
CAPEX | -19.99M | - | - | - | - | |||||
EBITDA | - | - | - | - | 159M | |||||
D&A | 88.56M | 64.68M | 65.82M | 64.52M | 63M | |||||
Operating Income | 153M | 130M | 112M | 109M | 96M | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Others | 39.62M | 250M | 203M | 209M | 243M | |||||
Total Assets | 2.47B | 2.68B | 2.66B | 890M | 855M | |||||
CAPEX | -15.98M | - | - | - | - | |||||
EBITDA | - | - | - | - | -26M | |||||
D&A | 6.98M | 20.37M | 16.16M | 15.7M | 16M | |||||
Operating Income | -58.6M | -46.81M | 6.63M | 39.44M | -42M | |||||
Intersegments | -67.55M | -8.95M | - | - | - | |||||
Total Assets | -39.96M | -7M | - | - | - | |||||
Operating Income | -10.9M | 35.42M | 6.98M | - | - | |||||
Operating Income | -185M | -219M | -274M | -275M | -252M | |||||
EBITDA | - | - | - | - | -235M | |||||
Total Assets | - | - | - | - | 303M | |||||
Total Assets | 3.42B | 1.61B | 1.4B | 2.11B | 1.47B | |||||
CAPEX | -55.38M | - | - | - | - | |||||
D&A | 21.1M | 22.9M | 22.06M | 20.63M | 17M | |||||
Pharmaceutical Products | ||||||||||
Hospital | 141M | - | - | - | - | |||||
Total Assets | 269M | - | - | - | - | |||||
CAPEX | -12.62M | - | - | - | - | |||||
D&A | 12.06M | - | - | - | - | |||||
Operating Income | -7.74M | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
USA and Canada | 3.15B | 3.86B | 3.9B | 4.09B | 4.25B | |||||
Total Assets | 10.53B | 11.56B | 10.84B | 11.79B | 10.67B | |||||
CAPEX | -296M | - | - | - | - | |||||
Rest of World | 872M | 1.18B | 1.44B | 1.58B | 1.66B | |||||
Total Assets | 2.22B | 2.22B | 2.24B | 396M | 457M | |||||
CAPEX | -9.76M | - | - | - | - | |||||
Rest of European Union | 544M | 712M | 893M | 1.12B | 1.2B | |||||
Total Assets | 5.39B | 6.6B | 7.05B | 7.58B | 6.94B | |||||
CAPEX | -91.39M | - | - | - | - | |||||
Spain | 362M | 321M | 363M | 423M | 418M | |||||
Total Assets | 1.09B | 1.16B | 1.19B | 1.64B | 1.64B | |||||
CAPEX | -71.02M | - | - | - | - | |||||
Unallocated Raw Material & Others | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Equities
- GRF Stock
- Financials Grifols, S.A.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















